

October 9, 2025



## IceCure Medical to Attend the 2025 Maxim Growth Summit

*IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer*

CAESAREA, Israel, Oct. 9, 2025 /PRNewswire/ -- [IceCure Medical Ltd.](#) (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that members of the Company's management, including Eyal Shamir, Chief Executive Officer, will be participating in Maxim's Growth Summit held in New York City on October 22<sup>nd</sup> and 23<sup>rd</sup>, 2025. The Company management will be meeting with institutional investors in a one-on-one format and will provide an overview of the Company, including its latest regulatory and commercial milestones in the U.S. and global markets.



IceCure's ProSense® cryoablation system recently [received](#) the U.S. Food and Drug Administration's ("FDA") marketing authorization for the local treatment of early-stage, low risk breast cancer in patients ≥70 years of age and women not suitable for surgery for breast cancer treatment. ProSense® offers the first new innovation in the treatment of women with low-risk early-stage breast cancer in decades and has the potential to set a new standard of care for the defined indication.

Investors should reach out to their Maxim sales representatives, or Michael Polyviou at [mpolyviou@evcgroup.com](mailto:mpolyviou@evcgroup.com) to schedule meetings with IceCure Medical's management team.

### About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its

minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

## **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses the participation of members of management at the Maxim Growth Summit. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, [www.sec.gov](http://www.sec.gov). The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Information available on or through the websites mentioned in this press release does not form part of this press release.

## **IR Contact:**

Email: [investors@icecure-medical.com](mailto:investors@icecure-medical.com)

Michael Polyviou

Phone: 732-232-6914

Logo - [https://mma.prnewswire.com/media/2319310/IceCure\\_Medical\\_Logo.jpg](https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg)

View original content: <https://www.prnewswire.com/news-releases/icecure-medical-to-attend-the-2025-maxim-growth-summit-302579488.html>

SOURCE IceCure Medical